CEBPα cooperating with Sp1 was reported to induce miR-122 expression by binding to its promoter in hepatocellular carcinoma cells [44], and miR-122 is a potential therapeutic target for the treatment of liver disease [45]. Here, SP1 is linked to liver disorder.